Mario E. Lacouture, MD, discusses the psychosocial impact of dermatologic adverse events from novel therapies in melanoma.
Mario E. Lacouture, MD, dermatologist, Memorial Sloan Kettering Cancer Center, discusses the psychosocial impact of dermatologic adverse events from novel therapies in melanoma.
This impact has been demonstrated in questionnaires from several studies. Lacouture says he has encountered patients who are not willing to go to work because they do not want to disclose that an acneiform rash is from treatment for melanoma. Lacouture has also seen patients who have been unable to sleep because of rash or pruritus.
Finally, he says that both physicians and nurses need to focus on helping their patients live better as well as longer.
Pembrolizumab Plus Chemo Improves Overall Survival in Resectable Gastric Cancer
Ibrutinib-Venetoclax Combo Elicits Durable Complete Responses in TP53+ MCL
Brentuximab Vedotin Triplet Provides Stronger Survival Signal vs R2 in R/R DLBCL
Durvalumab Plus Chemo Shows Sustained Survival Benefit in Advanced Biliary Tract Cancer
2 Commerce Drive
Cranbury, NJ 08512